Elevance Health said on July 28, 2025 its Board of Directors elected Steven H. Collis to serve as an independent director, effective August 1, 2025, with a term expiring at the company's 2027 annual meeting of shareholders.

1. 01

   Elevance Health said on July 28, 2025 its Board of Directors elected Steven H. Collis to serve as an independent director, effective August 1, 2025, with a term expiring at the company's 2027 annual meeting of shareholders.

2. 02

   The company said the Board appointed Collis to the Audit and Finance Committees and determined that he qualifies as an "audit committee financial expert" as defined in SEC regulations.

3. 03

   Elevance Health said Collis will receive compensation for his services as a director in accordance with the company's standard compensation program for non-employee directors, and that there is no arrangement or understanding between Mr. Collis and any other person pursuant to which he was elected to the Board, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a).

4. 04

   The company said Collis currently serves as Executive Chairman of the Board of Cencora (formerly AmerisourceBergen), joined Cencora in 1994, became President and Chief Executive Officer in 2011, and became Executive Chairman in 2024. It said his tenure as President and CEO was 13 years.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.